Lundbeck A/S today announced that new migraine clinical data will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place 27–30 June in Geneva, Switzerland…. read more.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium… read more.
Shingles vaccination reduces dementia risk, researchers reported on June 15, 2026 in the Annals of Internal Medicine. “Receipt of RZV [recombinant shingles vaccine] during admission to a skilled-nursing… read more.
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced new clinician-reported data in patients with intellectual and developmental disabilities demonstrating meaningful and rapid improvements in tardive dyskinesia severity, as well as improvements… read more.
Researchers found postoperative delirium was strongly associated with long-term cognitive decline and the effect was not explained by rehospitalizations, highlighting the long-term impact of delirium on brain health…. read more.
Amid growing concern about the widespread off‑label use of sedative medications for sleep problems, Flinders University researchers have led a world‑first clinical trial examining how a commonly prescribed… read more.
Ipsen announced results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport (abobotulinumtoxinA) to Botox (onabotulinumtoxinA) in adults living with upper limb spasticity (ULS) will be presented as a late-breaking presentation… read more.
Genentech has received FDA approval of Ocrevus (ocrelizumab) intravenous (IV) infusion for the treatment of relapsing-remitting multiple sclerosis (RRMS) in pediatric patients 10 years of age and older who… read more.
Roche announced that it has received CE Mark for Elecsys pTau217, a blood test developed in collaboration with Eli Lilly and Company and designed to measure the phosphorylated… read more.
Treatment with CGRP inhibitors, a class of drugs used to prevent migraine, appears to be associated with a reduced risk of glaucoma, researchers reported on May 6, 2026… read more.
NICE(UK): Vorasidenib can be used as an option to treat grade 2 astrocytoma or oligodendroglioma in people 12 years and over when: i) the cancer has a susceptible… read more.
People with insurance through an employer or another commercial plan experienced an average wait time of 50 days for their first visit with a neurology provider, according to… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
